NanoString Announces Collaboration with National Cancer Institute to Improve Cancer Immunotherapy Biomarker Discovery
June 04 2018 - 6:00AM
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life
science tools for translational research and molecular diagnostic
products, today announced a collaboration with the Cancer Therapy
Evaluation Program (CTEP) of the National Cancer Institute (NCI) to
facilitate the clinical validation and utility of novel
immune-based gene signatures to better inform treatment
decisions.
The collaboration supports NCI/CTEP efforts to
implement novel strategies to correlate therapeutic treatment with
patient response across a range of tumor types by incorporating the
PanCancer IO 360TM Gene Expression Panel into select active and
future NCI-sponsored clinical trials.
The PanCancer IO360 panel consists of 770 genes
and is designed to characterize mechanisms of tumor immune evasion
and identify targetable therapeutic pathways by leveraging several
gene signatures to describe key biological processes. The panel is
designed around the Tumor Inflammation Signature (TIS), an 18 gene
signature which measures the presence or absence of a peripherally
suppressed adaptive immune response within the tumor that enriches
for patient response to a variety of different cancer
immunotherapies (Cesano & Warren
https://www.ncbi.nlm.nih.gov/pubmed/29393888). The panel contains
additional gene expression signatures to characterize the presence
of immune cells within the tumor microenvironment and key
biological activities such as IFN signaling, expression of key
immune checkpoint molecules, antigenic burden (DNA mismatch repair
status and MAGE expression), antigen processing and presentation,
oxygenation/hypoxia, and vascularization.
“We believe that this collaboration presents a
unique opportunity to apply in the translational research setting
the latest generation of transcriptional profiling tools to
NCI-sponsored clinical trials and to accelerate the development and
implementation of novel immunotherapies and related diagnostics,”
said Alessandra Cesano, chief medical officer at NanoString.
One of the first NCI-sponsored clinical trials
to be included in the collaboration is led by Dr. Stephen Hodi. “By
expanding the use of gene expression profiling, we may help
investigators better understand and potentially predict response to
novel immuno-modulatory combinations such as Pembrolizumab +
ziv-aflibercept,” said Dr. Stephen Hodi, Director of the Melanoma
Center and the Center for Immuno-Oncology at Dana-Farber Cancer
Institute.
About NanoString Technologies
NanoString Technologies provides life science
tools for translational research and molecular diagnostic products.
The company’s nCounter® Analysis System has been employed in life
sciences research since it was first introduced in 2008 and has
been cited in more than 2,000 peer-reviewed publications. The
nCounter Analysis System offers a cost-effective way to easily
profile the expression of hundreds of genes, proteins, miRNAs, or
copy number variations, simultaneously with high sensitivity and
precision, facilitating a wide variety of basic research and
translational medicine applications, including biomarker discovery
and validation. The company's technology is also being used in
diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature
Assay together with the nCounter Dx Analysis System
is FDA 510(k) cleared for use as a prognostic indicator
for distant recurrence of breast cancer. In addition, the company
collaborates with biopharmaceutical companies in the development of
companion diagnostic tests for various cancer therapies, helping to
realize the promise of precision oncology. For more information,
please visit www.nanostring.com.
About the PanCancer IO360
NanoString’s PanCancer IO 360 Gene Expression
Panel is a unique 770 gene expression panel for research use only
that combines vital components involved in the complex interplay
between the tumor, microenvironment and immune response in cancer
allowing for a multifaceted characterization of disease biology and
interrogation of mechanisms of immune evasion. Developed
specifically for translational research, this powerful new panel
incorporates 47 potentially predictive Research Use Only biological
signatures including the 18-gene Tumor Inflammation
Signature.
Contact:Doug Farrell Vice President, Investor Relations &
Corporate Communications dfarrell@nanostring.com Phone:
206-602-1768
NanoString Technologies (NASDAQ:NSTG)
Historical Stock Chart
From Aug 2024 to Sep 2024
NanoString Technologies (NASDAQ:NSTG)
Historical Stock Chart
From Sep 2023 to Sep 2024